CVS Health Corporation (CVS) shares recently saw a decrease, trading at $67.46, marking a 2.86% decline from their previous close. This shift comes despite an intraday high of $70.32 and a low of $67.04, with a volume of over 14 million shares during the day.
In September 2024, CVS began reconsidering its strategic structure, contemplating the separation of its retail and insurance units—a significant move following its $70 billion acquisition of Aetna back in 2017. The company's struggles are underscored by a substantial 40% drop in share price this year and a troublesome medical loss ratio of 95.2%, as reported by Reuters.
However, CVS continues to provide a forward dividend yield of 4.8%, attracting income-seeking investors. With a decade-long history of dividend growth at 142%, the company maintains a "Moderate Buy" consensus rating among analysts. They predict a moderate upside potential based on a price target of $69.82 and project earnings and revenue growth in the future, signaling potential long-term stability.